Discovery Laboratories (DSCO -3.7%) says it will present data on two of its key products,...

|By:, SA News Editor

Discovery Laboratories (DSCO -3.7%) says it will present data on two of its key products, Surfaxin and Afectair, at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Surfaxin is the first FDA-approved synthetic, peptide-containing surfactant for the prevention of respiratory distress syndrome in premature high risk infants, while in February 2012 Afectair, a ventilator circuit that simplifies the delivery of inhaled therapies to critical care patients requiring ventilator support, was recently cleared with the FDA for marketing in the U.S.